HitGen and Cambridge Molecular Announce a Strategic Partnership, Bringing Together DNA-Encoded Libraries and Deep Learning

HitGen Inc. and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly optimised DEL-specific deep learning system – as an addition to HitGen’s world-leading DEL discovery platform, with over 1 trillion drug-like small molecules.

DeepDELve 2 is a robust and highly specialised deep learning pipeline that provides a pathway to readily available potential ligands for drug targets. It leverages all the useful information delivered by a DEL selection set to extract high-level patterns, and identifies readily available predicted ligands from within commercially available or internal compound collections. It has undergone constant use and iteration for the past year with external partners, and is, to our knowledge, the most advanced such system currently deployed.

Recommended AI News: Climate Choices Research and System Plan Released by ChoiceFlows to Support Main Street Climate Decision Making

DeepDELve 2 is fully integrated with Enamine REAL space, Mcule, Chemspace, and eleven other compound catalogue providers, and can be linked on demand to commercial or internal catalogues of choice. As such, potential ligands are often delivered to a partner’s lab in as little as a few days. The system can be run both on maximum confidence and maximum diversity settings, and is capable of analysing a variety of selection set-ups, including selectivity screens and other multi-condition screens. It has been road-tested on a wide range of screening outcomes with compelling results, and can be trained in a privacy-preserving manner that does not require partners to share molecular structures from their selections.

“By combining the scale and success of HitGen’s DEL technology with Cambridge Molecular’s powerful machine learning capabilities, we are witnessing the emergence of a highly effective approach to accessing expanded chemical space for drug discovery via available chemical providers or even virtual enumerated chemical designs. We look forward to further accelerating and empowering our partners in discovering and developing innovative medicines,” said Dr Jin Li, Chairman and CEO of HitGen Inc.

“We are pleased to take part in a paradigm shift in the DEL space with a partner as forward-thinking, determined and effective as HitGen. A new capability with such an impact on the number and diversity of confirmed leads, and on the speed of lead acquisition, has the potential to transform the industry, enabling HitGen partners to access novel chemical space reliably and quickly, allowing faster iterations, and yielding more backup series. This is a once-in-a-generation opportunity,” said Dmitry Foxham, CEO of Cambridge Molecular.

Recommended AI News: Hitachi Astemo Sees Sweeping Changes In Manufacturing On Horizon

[To share your insights with us, please write to sghosh@martechseries.com]